Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 39.14B | 39.14B | 39.10B | 38.98B | 36.78B | 36.50B |
Gross Profit | 12.62B | 12.62B | 12.49B | 15.74B | 15.42B | 15.33B |
EBITDA | 9.69B | 8.75B | 10.71B | 10.25B | 10.25B | 10.18B |
Net Income | 1.52B | 1.52B | 2.80B | 4.32B | 4.37B | 4.96B |
Balance Sheet | ||||||
Total Assets | 97.89B | 97.89B | 100.04B | 102.18B | 98.97B | 105.64B |
Cash, Cash Equivalents and Short-Term Investments | 22.00B | 22.00B | 19.42B | 18.86B | 14.36B | 20.55B |
Total Debt | 13.67B | 13.67B | 5.82B | 8.89B | 10.00B | 330.00M |
Total Liabilities | 23.56B | 23.56B | 13.92B | 18.50B | 18.97B | 9.69B |
Stockholders Equity | 74.32B | 74.32B | 86.11B | 83.61B | 79.96B | 95.88B |
Cash Flow | ||||||
Free Cash Flow | 6.53B | 6.53B | 4.32B | 7.78B | 5.30B | -686.00M |
Operating Cash Flow | 11.76B | 11.76B | 7.12B | 9.18B | 8.50B | 6.85B |
Investing Cash Flow | -4.12B | -4.12B | -3.26B | -1.95B | -3.81B | -6.95B |
Financing Cash Flow | -5.46B | -5.46B | -3.89B | -3.14B | -11.05B | -2.50B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | 144.86B | 17.88 | 6.62% | 3.62% | 2.72% | -6.31% | |
75 Outperform | 125.12B | 22.94 | 12.01% | 3.07% | 5.82% | -20.09% | |
73 Outperform | 177.22B | 34.45 | 7.08% | 2.51% | 10.98% | -76.45% | |
69 Neutral | $73.65B | 90.57 | 1.63% | 1.61% | -0.91% | -52.71% | |
60 Neutral | 19.15B | 13.83 | 6.72% | 2.32% | 11.12% | 20.54% | |
60 Neutral | 11.12B | -40.09 | 0.22% | 3.74% | 3.36% | -310.49% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Hogy Medical Co., Ltd. addressed recent media reports suggesting its potential privatization, clarifying that while it is considering various options to enhance corporate value, no official decision has been made. This announcement indicates the company’s strategic exploration to potentially reposition itself in the market, though stakeholders should note that no concrete plans have been finalized.
Hogy Medical Co., Ltd. reported a decline in its financial performance for the three months ended June 30, 2025, with net sales and profits decreasing compared to the previous year. Despite the downturn, the company plans to increase its annual dividends per share and forecasts a positive growth in net sales and profits for the full fiscal year ending March 31, 2026, indicating a strategic focus on long-term growth and shareholder value.
Hogy Medical Co., Ltd. announced the results of its 64th Annual General Meeting of Shareholders, where the proposal for the election of directors was approved. Although one director candidate nominated by shareholders was elected, the company noted that this individual does not meet its criteria for independence. The newly elected director is expected to strengthen management oversight, contributing from a unique perspective compared to the current independent directors.
Hogy Medical Co., Ltd. announced significant changes to its Board of Directors and executive officers, effective June 20, 2025, and July 1, 2025, respectively. These changes are expected to enhance the company’s leadership structure, potentially impacting its strategic direction and operational efficiency, which could have implications for stakeholders and the company’s market positioning.